{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:56:38Z","timestamp":1777859798885,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"am","delay-in-days":321,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-53-01"],"award-info":[{"award-number":["ANR-10-LABX-53-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jconrel.2019.04.005","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T12:32:19Z","timestamp":1554985939000},"page":"24-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration"],"prefix":"10.1016","volume":"303","author":[{"given":"Thomas","family":"S\u00e9cher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Dalonneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Parent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Azzopardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Paintaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustapha","family":"Si-Tahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Heuz\u00e9-Vourc'h","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2019.04.005_bb0005","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1086\/593186","article-title":"Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease","volume":"47","author":"Martinez-Solano","year":"2008","journal-title":"Clinical Infect. Dis."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0010","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/thorax.57.9.759","article-title":"Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations","volume":"57","author":"Patel","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.jconrel.2019.04.005_bb0015","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1164\/ajrccm.165.7.2105078","article-title":"Ventilator-associated pneumonia","volume":"165","author":"Chastre","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0020","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1179\/joc.2004.16.5.437","article-title":"Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States","volume":"16","author":"Friedland","year":"2004","journal-title":"J. Chemother."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/dkp201","article-title":"Update on the treatment of Pseudomonas aeruginosa pneumonia","volume":"64","author":"El Solh","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2019.04.005_bb0030","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1086\/504477","article-title":"Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa","volume":"43","author":"Bonomo","year":"2006","journal-title":"Clinical Infect. Dis."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pharmthera.2018.05.003","article-title":"Therapeutic antibodies: a new era in the treatment of respiratory diseases?","volume":"189","author":"Secher","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0040","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal fc receptor (FcRn)","volume":"281","author":"Dall'Acqua","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0045","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1067\/mai.2001.116576","article-title":"Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys","volume":"108","author":"Hart","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0050","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1592\/phco.26.6.813","article-title":"Pharmacokinetics of intravenous immunoglobulin: a systematic review","volume":"26","author":"Koleba","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jconrel.2019.04.005_bb0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0060","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1165\/rcmb.2012-0031OC","article-title":"Nebulized anti-IL-13 monoclonal antibody Fab' fragment reduces allergen-induced asthma","volume":"47","author":"Hacha","year":"2012","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0065","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1128\/IAI.74.5.3068-3070.2006","article-title":"Administration of antibody to the lung protects mice against pneumonic plague","volume":"74","author":"Hill","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2014.05.021","article-title":"PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract","volume":"187","author":"Koussoroplis","year":"2014","journal-title":"J. Control. Rel."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0075","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s11095-007-9481-3","article-title":"Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization","volume":"25","author":"Maillet","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0080","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.4161\/mabs.29938","article-title":"Effect of formulation on the stability and aerosol performance of a nebulized antibody","volume":"6","author":"Respaud","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.jconrel.2019.04.005_bb0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jconrel.2016.05.018","article-title":"Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin","volume":"234","author":"Respaud","year":"2016","journal-title":"J. Control. Rel."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0090","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1517\/17425247.2015.999039","article-title":"Nebulization as a delivery method for mAbs in respiratory diseases","volume":"12","author":"Respaud","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0095","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jconrel.2014.10.003","article-title":"Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system","volume":"196","author":"Guilleminault","year":"2014","journal-title":"J. Control. Rel."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0100","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.4161\/mabs.34454","article-title":"VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations","volume":"6","author":"Herve","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.jconrel.2019.04.005_bb0105","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s11095-011-0442-5","article-title":"The airways, a novel route for delivering monoclonal antibodies to treat lung tumors","volume":"28","author":"Maillet","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0110","first-page":"1","article-title":"Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs","author":"Mora","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.jconrel.2019.04.005_bb0115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1128\/AAC.01802-15","article-title":"Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection","volume":"60","author":"Detalle","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jmb.2012.11.036","article-title":"The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation","volume":"425","author":"Lightwood","year":"2013","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-8518-1-2","article-title":"Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model","volume":"1","author":"Faure","year":"2003","journal-title":"J. Immune Based Therapies Vaccines"},{"key":"10.1016\/j.jconrel.2019.04.005_bb0130","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/341069","article-title":"Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV","volume":"186","author":"Frank","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0135","article-title":"Pulmonary permeability assessed by fluorescent-labeled dextran instilled intranasally into mice with LPS-induced acute lung injury","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2019.04.005_bb0140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jim.2005.06.014","article-title":"An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen","volume":"304","author":"Patton","year":"2005","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2019.04.005_bb0145","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1258\/la.2007.06014e","article-title":"Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies","volume":"42","author":"Kukavica-Ibrulj","year":"2008","journal-title":"Lab. Anim."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0150","doi-asserted-by":"crossref","first-page":"R62","DOI":"10.1186\/cc10036","article-title":"Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study","volume":"15","author":"Magret","year":"2011","journal-title":"Crit. Care"},{"key":"10.1016\/j.jconrel.2019.04.005_bb0155","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.micinf.2011.07.011","article-title":"Innate immune responses to Pseudomonas aeruginosa infection","volume":"13","author":"Lavoie","year":"2011","journal-title":"Microbes Infect."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4161\/viru.25436","article-title":"Host innate immune responses to sepsis","volume":"5","author":"Wiersinga","year":"2014","journal-title":"Virulence"},{"key":"10.1016\/j.jconrel.2019.04.005_bb0165","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.vaccine.2007.12.007","article-title":"Vaccines and immunotherapy against Pseudomonas aeruginosa","volume":"26","author":"Doring","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2019.04.005_bb0170","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4161\/hv.7.10.16369","article-title":"Recent developments for Pseudomonas vaccines","volume":"7","author":"Sharma","year":"2011","journal-title":"Human Vaccines"},{"key":"10.1016\/j.jconrel.2019.04.005_bb0175","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1128\/AAC.00290-15","article-title":"Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies","volume":"59","author":"Leyva-Grado","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0180","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1128\/CVI.00002-10","article-title":"Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice","volume":"17","author":"Ye","year":"2010","journal-title":"Clini. Vaccine Immunol."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0185","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/jac\/dkr038","article-title":"Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection","volume":"66","author":"Secher","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0190","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1093\/emboj\/cdg499","article-title":"Oligomerization of type III secretion proteins PopB and PopD precedes pore formation in Pseudomonas","volume":"22","author":"Schoehn","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0195","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/CCM.0b013e3182377906","article-title":"Clinical outcomes of type III Pseudomonas aeruginosa bacteremia","volume":"40","author":"El-Solh","year":"2012","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0200","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1165\/rcmb.2008-0202OC","article-title":"Effect of IL-10 on neutrophil recruitment and survival after Pseudomonas aeruginosa challenge","volume":"41","author":"Sun","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0205","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1172\/JCI7124","article-title":"Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia","volume":"104","author":"Kurahashi","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0210","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1164\/ajrccm.160.1.9808096","article-title":"Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients","volume":"160","author":"Muhlebach","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0215","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1164\/rccm.200208-794OC","article-title":"Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease","volume":"168","author":"Qiu","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0220","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1165\/rcmb.2004-0124TR","article-title":"Lung inflammation as a therapeutic target in cystic fibrosis","volume":"31","author":"Koehler","year":"2004","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0225","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/INF.0000000000000339","article-title":"Epidemiology and clinical outcomes of multidrug-resistant, gram-negative bloodstream infections in a European tertiary pediatric hospital during a 12-month period","volume":"33","author":"Folgori","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.jconrel.2019.04.005_bb0230","series-title":"WHO Publishes List of Bacteria for which New Antibiotics Are Urgently Needed","author":"W.D.o. Communications","year":"2017"},{"key":"10.1016\/j.jconrel.2019.04.005_bb0235","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1097\/CCM.0b013e31825334f6","article-title":"Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial","volume":"40","author":"Francois","year":"2012","journal-title":"Crit. Care Med."},{"issue":"4","key":"10.1016\/j.jconrel.2019.04.005_bb0240","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jcf.2017.12.006","article-title":"KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa","volume":"17","author":"Jain","year":"2018","journal-title":"J. Cystic Fibrosis"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591930197X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591930197X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:37:55Z","timestamp":1777509475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836591930197X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":48,"alternative-id":["S016836591930197X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.04.005","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}